Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

PI3Kγ/δ and NOTCH1 Cross-Regulate Pathways That Define the T-cell Acute Lymphoblastic Leukemia Disease Signature.

Efimenko E, Davé UP, Lebedeva IV, Shen Y, Sanchez-Quintero MJ, Diolaiti D, Kung A, Lannutti BJ, Chen J, Realubit R, Niatsetskaya Z, Ten V, Karan C, Chen X, Califano A, Diacovo TG.

Mol Cancer Ther. 2017 Oct;16(10):2069-2082. doi: 10.1158/1535-7163.MCT-17-0141. Epub 2017 Jul 17.

2.

Formation of Nickel Clusters Wrapped in Carbon Cages: Toward New Endohedral Metallofullerene Synthesis.

Sinitsa AS, Chamberlain TW, Zoberbier T, Lebedeva IV, Popov AM, Knizhnik AA, McSweeney RL, Biskupek J, Kaiser U, Khlobystov AN.

Nano Lett. 2017 Feb 8;17(2):1082-1089. doi: 10.1021/acs.nanolett.6b04607. Epub 2017 Jan 18.

3.

[Dental and oncological status of patients with tongue carcinoma].

Davydov AB, Lebedev SN, Lebedeva IV, Davydova OB.

Stomatologiia (Mosk). 2015;94(1):25-29. doi: 10.17116/stomat201594125-29. Russian.

PMID:
25909610
4.

Energetics of atomic scale structure changes in graphene.

Skowron ST, Lebedeva IV, Popov AM, Bichoutskaia E.

Chem Soc Rev. 2015 May 21;44(10):3143-76. doi: 10.1039/c4cs00499j. Epub 2015 Mar 26. Review.

PMID:
25811047
5.

The atomistic mechanism of carbon nanotube cutting catalyzed by nickel under an electron beam.

Lebedeva IV, Chamberlain TW, Popov AM, Knizhnik AA, Zoberbier T, Biskupek J, Kaiser U, Khlobystov AN.

Nanoscale. 2014 Dec 21;6(24):14877-90. doi: 10.1039/c4nr05006a. Epub 2014 Nov 3.

PMID:
25363681
6.

Formation of nickel-carbon heterofullerenes under electron irradiation.

Sinitsa AS, Lebedeva IV, Knizhnik AA, Popov AM, Skowron ST, Bichoutskaia E.

Dalton Trans. 2014 May 28;43(20):7499-513. doi: 10.1039/c3dt53385a.

PMID:
24695822
7.

AA stacking, tribological and electronic properties of double-layer graphene with krypton spacer.

Popov AM, Lebedeva IV, Knizhnik AA, Lozovik YE, Potapkin BV, Poklonski NA, Siahlo AI, Vyrko SA.

J Chem Phys. 2013 Oct 21;139(15):154705. doi: 10.1063/1.4824298.

PMID:
24160531
8.

Approaches to modelling irradiation-induced processes in transmission electron microscopy.

Skowron ST, Lebedeva IV, Popov AM, Bichoutskaia E.

Nanoscale. 2013 Aug 7;5(15):6677-92. doi: 10.1039/c3nr02130k.

PMID:
23783785
9.

Ab initio study of edge effect on relative motion of walls in carbon nanotubes.

Popov AM, Lebedeva IV, Knizhnik AA, Lozovik YE, Potapkin BV.

J Chem Phys. 2013 Jan 14;138(2):024703. doi: 10.1063/1.4774083.

PMID:
23320709
10.

Chiral graphene nanoribbon inside a carbon nanotube: ab initio study.

Lebedeva IV, Popov AM, Knizhnik AA, Khlobystov AN, Potapkin BV.

Nanoscale. 2012 Aug 7;4(15):4522-9. doi: 10.1039/c2nr30144j. Epub 2012 Jun 13.

PMID:
22696165
11.

Sensitive and specific fluorescent probes for functional analysis of the three major types of mammalian ABC transporters.

Lebedeva IV, Pande P, Patton WF.

PLoS One. 2011;6(7):e22429. doi: 10.1371/journal.pone.0022429. Epub 2011 Jul 22.

12.

Effect of Peierls transition in armchair carbon nanotube on dynamical behaviour of encapsulated fullerene.

Poklonski NA, Vyrko SA, Kislyakov EF, Hieu NN, Bubel' ON, Popov AM, Lozovik YE, Knizhnik AA, Lebedeva IV, Viet NA.

Nanoscale Res Lett. 2011 Mar 14;6(1):216. doi: 10.1186/1556-276X-6-216.

13.

Diffusion and drift of graphene flake on graphite surface.

Lebedeva IV, Knizhnik AA, Popov AM, Ershova OV, Lozovik YE, Potapkin BV.

J Chem Phys. 2011 Mar 14;134(10):104505. doi: 10.1063/1.3557819.

PMID:
21405173
14.

Interlayer interaction and relative vibrations of bilayer graphene.

Lebedeva IV, Knizhnik AA, Popov AM, Lozovik YE, Potapkin BV.

Phys Chem Chem Phys. 2011 Apr 7;13(13):5687-95. doi: 10.1039/c0cp02614j. Epub 2011 Feb 10.

PMID:
21311778
15.

The development of MDA-7/IL-24 as a cancer therapeutic.

Dent P, Yacoub A, Hamed HA, Park MA, Dash R, Bhutia SK, Sarkar D, Wang XY, Gupta P, Emdad L, Lebedeva IV, Sauane M, Su ZZ, Rahmani M, Broaddus WC, Young HF, Lesniak MS, Grant S, Curiel DT, Fisher PB.

Pharmacol Ther. 2010 Nov;128(2):375-84. doi: 10.1016/j.pharmthera.2010.08.001. Epub 2010 Aug 21. Review.

16.

MDA-7/IL-24 as a cancer therapeutic: from bench to bedside.

Dent P, Yacoub A, Hamed HA, Park MA, Dash R, Bhutia SK, Sarkar D, Gupta P, Emdad L, Lebedeva IV, Sauane M, Su ZZ, Rahmani M, Broaddus WC, Young HF, Lesniak M, Grant S, Curiel DT, Fisher PB.

Anticancer Drugs. 2010 Sep;21(8):725-31. doi: 10.1097/CAD.0b013e32833cfbe1. Review.

17.

Dissipation and fluctuations in nanoelectromechanical systems based on carbon nanotubes.

Lebedeva IV, Knizhnik AA, Popov AM, Lozovik YE, Potapkin BV.

Nanotechnology. 2009 Mar 11;20(10):105202. doi: 10.1088/0957-4484/20/10/105202. Epub 2009 Feb 16.

PMID:
19417512
18.

Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24.

Emdad L, Lebedeva IV, Su ZZ, Gupta P, Sauane M, Dash R, Grant S, Dent P, Curiel DT, Sarkar D, Fisher PB.

Cancer Biol Ther. 2009 Mar;8(5):391-400. Epub 2009 Mar 8. Review.

PMID:
19276652
19.

Mechanism of in vitro pancreatic cancer cell growth inhibition by melanoma differentiation-associated gene-7/interleukin-24 and perillyl alcohol.

Lebedeva IV, Su ZZ, Vozhilla N, Chatman L, Sarkar D, Dent P, Athar M, Fisher PB.

Cancer Res. 2008 Sep 15;68(18):7439-47. doi: 10.1158/0008-5472.CAN-08-0072. Epub 2008 Sep 3.

20.

Chemoprevention by perillyl alcohol coupled with viral gene therapy reduces pancreatic cancer pathogenesis.

Lebedeva IV, Su ZZ, Vozhilla N, Chatman L, Sarkar D, Dent P, Athar M, Fisher PB.

Mol Cancer Ther. 2008 Jul;7(7):2042-50. doi: 10.1158/1535-7163.MCT-08-0245.

21.

Autocrine regulation of mda-7/IL-24 mediates cancer-specific apoptosis.

Sauane M, Su ZZ, Gupta P, Lebedeva IV, Dent P, Sarkar D, Fisher PB.

Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9763-8. doi: 10.1073/pnas.0804089105. Epub 2008 Jul 3.

22.

Apoptotic activity and mechanism of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic-acid and related synthetic triterpenoids in prostate cancer.

Hyer ML, Shi R, Krajewska M, Meyer C, Lebedeva IV, Fisher PB, Reed JC.

Cancer Res. 2008 Apr 15;68(8):2927-33. doi: 10.1158/0008-5472.CAN-07-5759.

23.

Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling.

Yacoub A, Gupta P, Park MA, Rhamani M, Hamed H, Hanna D, Zhang G, Sarkar D, Lebedeva IV, Emdad L, Koumenis C, Curiel DT, Grant S, Fisher PB, Dent P.

Mol Cancer Ther. 2008 Feb;7(2):314-29. doi: 10.1158/1535-7163.MCT-07-2150.

24.

Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells.

Yacoub A, Park MA, Gupta P, Rahmani M, Zhang G, Hamed H, Hanna D, Sarkar D, Lebedeva IV, Emdad L, Sauane M, Vozhilla N, Spiegel S, Koumenis C, Graf M, Curiel DT, Grant S, Fisher PB, Dent P.

Mol Cancer Ther. 2008 Feb;7(2):297-313. doi: 10.1158/1535-7163.MCT-07-2166.

25.

Targeted combinatorial therapy of non-small cell lung carcinoma using a GST-fusion protein of full-length or truncated MDA-7/IL-24 with Tarceva.

Gupta P, Emdad L, Lebedeva IV, Sarkar D, Dent P, Curiel DT, Settleman J, Fisher PB.

J Cell Physiol. 2008 Jun;215(3):827-36. doi: 10.1002/jcp.21369.

PMID:
18270968
26.

Antisense oligonucleotides in cancer: recent advances.

Lebedeva IV, Stein CA.

BioDrugs. 2000 Mar;13(3):195-216.

PMID:
18034525
27.

Melanoma differentiation associated gene-7/interleukin-24 reverses multidrug resistance in human colorectal cancer cells.

Emdad L, Lebedeva IV, Su ZZ, Sarkar D, Dent P, Curiel DT, Fisher PB.

Mol Cancer Ther. 2007 Nov;6(11):2985-94.

28.
29.

mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review).

Lebedeva IV, Emdad L, Su ZZ, Gupta P, Sauane M, Sarkar D, Staudt MR, Liu SJ, Taher MM, Xiao R, Barral P, Lee SG, Wang D, Vozhilla N, Park ES, Chatman L, Boukerche H, Ramesh R, Inoue S, Chada S, Li R, De Pass AL, Mahasreshti PJ, Dmitriev IP, Curiel DT, Yacoub A, Grant S, Dent P, Senzer N, Nemunaitis JJ, Fisher PB.

Int J Oncol. 2007 Nov;31(5):985-1007. Review.

PMID:
17912425
30.

Eradication of therapy-resistant human prostate tumors using a cancer terminator virus.

Sarkar D, Lebedeva IV, Su ZZ, Park ES, Chatman L, Vozhilla N, Dent P, Curiel DT, Fisher PB.

Cancer Res. 2007 Jun 1;67(11):5434-42.

31.

Melanoma differentiation associated gene-7 (mda-7)/IL-24: a 'magic bullet' for cancer therapy?

Sarkar D, Lebedeva IV, Gupta P, Emdad L, Sauane M, Dent P, Curiel DT, Fisher PB.

Expert Opin Biol Ther. 2007 May;7(5):577-86. Review.

PMID:
17477796
32.

Strategy for reversing resistance to a single anticancer agent in human prostate and pancreatic carcinomas.

Lebedeva IV, Washington I, Sarkar D, Clark JA, Fine RL, Dent P, Curiel DT, Turro NJ, Fisher PB.

Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3484-9. Epub 2007 Feb 21.

33.

Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma.

Fisher PB, Sarkar D, Lebedeva IV, Emdad L, Gupta P, Sauane M, Su ZZ, Grant S, Dent P, Curiel DT, Senzer N, Nemunaitis J.

Toxicol Appl Pharmacol. 2007 Nov 1;224(3):300-7. Epub 2006 Nov 23. Review.

34.

N-glycosylation of MDA-7/IL-24 is dispensable for tumor cell-specific apoptosis and "bystander" antitumor activity.

Sauane M, Gupta P, Lebedeva IV, Su ZZ, Sarkar D, Randolph A, Valerie K, Gopalkrishnan RV, Fisher PB.

Cancer Res. 2006 Dec 15;66(24):11869-77.

35.

Combinatorial treatment of non-small-cell lung cancers with gefitinib and Ad.mda-7 enhances apoptosis-induction and reverses resistance to a single therapy.

Emdad L, Lebedeva IV, Su ZZ, Gupta P, Sarkar D, Settleman J, Fisher PB.

J Cell Physiol. 2007 Feb;210(2):549-59.

PMID:
17111370
36.

Targeting inhibition of K-ras enhances Ad.mda-7-induced growth suppression and apoptosis in mutant K-ras colorectal cancer cells.

Lebedeva IV, Su ZZ, Emdad L, Kolomeyer A, Sarkar D, Kitada S, Waxman S, Reed JC, Fisher PB.

Oncogene. 2007 Feb 1;26(5):733-44. Epub 2006 Aug 21.

PMID:
16924242
37.

BiP/GRP78 is an intracellular target for MDA-7/IL-24 induction of cancer-specific apoptosis.

Gupta P, Walter MR, Su ZZ, Lebedeva IV, Emdad L, Randolph A, Valerie K, Sarkar D, Fisher PB.

Cancer Res. 2006 Aug 15;66(16):8182-91.

38.

Ionizing radiation enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human ovarian cancer.

Emdad L, Sarkar D, Lebedeva IV, Su ZZ, Gupta P, Mahasreshti PJ, Dent P, Curiel DT, Fisher PB.

J Cell Physiol. 2006 Aug;208(2):298-306.

39.

Activation of Ras/Raf protects cells from melanoma differentiation-associated gene-5-induced apoptosis.

Lin L, Su Z, Lebedeva IV, Gupta P, Boukerche H, Rai T, Barber GN, Dent P, Sarkar D, Fisher PB.

Cell Death Differ. 2006 Nov;13(11):1982-93. Epub 2006 Mar 31.

40.

Molecular target-based therapy of pancreatic cancer.

Lebedeva IV, Sarkar D, Su ZZ, Gopalkrishnan RV, Athar M, Randolph A, Valerie K, Dent P, Fisher PB.

Cancer Res. 2006 Feb 15;66(4):2403-13.

41.

mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine.

Gupta P, Su ZZ, Lebedeva IV, Sarkar D, Sauane M, Emdad L, Bachelor MA, Grant S, Curiel DT, Dent P, Fisher PB.

Pharmacol Ther. 2006 Sep;111(3):596-628. Epub 2006 Feb 7. Review.

42.
43.

Unique aspects of mda-7/IL-24 antitumor bystander activity: establishing a role for secretion of MDA-7/IL-24 protein by normal cells.

Su Z, Emdad L, Sauane M, Lebedeva IV, Sarkar D, Gupta P, James CD, Randolph A, Valerie K, Walter MR, Dent P, Fisher PB.

Oncogene. 2005 Nov 17;24(51):7552-66.

PMID:
16044151
44.

mda-7/IL-24: exploiting cancer's Achilles' heel.

Lebedeva IV, Sauane M, Gopalkrishnan RV, Sarkar D, Su ZZ, Gupta P, Nemunaitis J, Cunningham C, Yacoub A, Dent P, Fisher PB.

Mol Ther. 2005 Jan;11(1):4-18. Review.

45.

Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis.

Lebedeva IV, Su ZZ, Sarkar D, Gopalkrishnan RV, Waxman S, Yacoub A, Dent P, Fisher PB.

Oncogene. 2005 Jan 20;24(4):585-96.

PMID:
15580305
46.

Human polynucleotide phosphorylase (hPNPaseold-35): a potential link between aging and inflammation.

Sarkar D, Lebedeva IV, Emdad L, Kang DC, Baldwin AS Jr, Fisher PB.

Cancer Res. 2004 Oct 15;64(20):7473-8.

47.

Mechanistic aspects of mda-7/IL-24 cancer cell selectivity analysed via a bacterial fusion protein.

Sauane M, Gopalkrishnan RV, Choo HT, Gupta P, Lebedeva IV, Yacoub A, Dent P, Fisher PB.

Oncogene. 2004 Oct 7;23(46):7679-90.

PMID:
15334067
48.

Infectivity enhanced adenoviral-mediated mda-7/IL-24 gene therapy for ovarian carcinoma.

Leath CA 3rd, Kataram M, Bhagavatula P, Gopalkrishnan RV, Dent P, Fisher PB, Pereboev A, Carey D, Lebedeva IV, Haisma HJ, Alvarez RD, Curiel DT, Mahasreshti PJ.

Gynecol Oncol. 2004 Aug;94(2):352-62.

PMID:
15297172
49.

MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells.

Yacoub A, Mitchell C, Hong Y, Gopalkrishnan RV, Su ZZ, Gupta P, Sauane M, Lebedeva IV, Curiel DT, Mahasreshti PJ, Rosenfeld MR, Broaddus WC, James CD, Grant S, Fisher PB, Dent P.

Cancer Biol Ther. 2004 Aug;3(8):739-51. Epub 2004 Aug 10.

PMID:
15197348
50.

Melanoma differentiation associated gene-7/interleukin-24 promotes tumor cell-specific apoptosis through both secretory and nonsecretory pathways.

Sauane M, Lebedeva IV, Su ZZ, Choo HT, Randolph A, Valerie K, Dent P, Gopalkrishnan RV, Fisher PB.

Cancer Res. 2004 May 1;64(9):2988-93.

Supplemental Content

Loading ...
Support Center